Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) shares, rose in value, with the stock price down by -7.69% to the previous day’s close as strong demand from buyers drove the stock to $2.04.
Actively observing the price movement in the last trading, the stock closed the session at $2.21. Referring to stock’s 52-week performance, its high was $3.79, and the low was $0.92. On the whole, LXRX has fluctuated by -7.69% over the past month.
With the market capitalization of Lexicon Pharmaceuticals Inc currently standing at about $502.33 million, investors are eagerly awaiting this quarter’s results, scheduled for Apr 30, 2024 – May 06, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.2, which is expected to increase to -$0.15 for fiscal year -$0.71 and then to about -$0.66 by fiscal year 2025. Data indicates that the EPS growth is expected to be 10.10% in 2025, while the next year’s EPS growth is forecast to be 7.00%.
Analysts have estimated the company’s revenue for the quarter at $1.37 million, with a low estimate of $1 million and a high estimate of $2.1 million. According to the average forecast, sales growth in current quarter could jump up 5,608.30%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $25.81 million, representing an increase of 2,043.70% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that LXRX’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of LXRX currently trading nearly -13.01% and -12.69% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 42.68, while the 7-day volatility ratio is showing 10.65% which for the 30-day chart, stands at 9.30%. Furthermore, Lexicon Pharmaceuticals Inc (LXRX)’s beta value is 1.29, and its average true range (ATR) is 0.23.
A comparison of Lexicon Pharmaceuticals Inc (LXRX) with its peers suggests the former has fared considerably weaker in the market. LXRX showed an intraday change of -7.69% in last session, and over the past year, it shrunk by -16.05%%.
Data on historical trading for Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) indicates that the trading volumes over the past 10 days have averaged 3.9 million and over the past 3 months, they’ve averaged 4.81 million. According to company’s latest data on outstanding shares, there are 244.92 million shares outstanding.
Nearly 2.73% of Lexicon Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 73.93% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 21.35 million shares as on Mar 15, 2024, resulting in a short ratio of 3.31. According to the data, the short interest in Lexicon Pharmaceuticals Inc (LXRX) stood at 8.67% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 23.41 million. The stock has risen by 33.33% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LXRX stock heading into the next quarter.
